KalkineWhat Is Putting Bod Australia (ASX:BOD) Back in Focus?
Highlights Bod Australia confirms its cannabidiol product achieves statistically significant results in a Phase IIb insomnia study. The result moves the company closer to becoming the first Australian group to offer a CBD-based insomnia treatment over the counter. A parallel clinical program targeting long-Covid symptoms continues to progress alongside the insomnia study. Bod Australia (ASX:BOD), the Melbourne-based cannabinoid drug development and consumer health company, has confirmed its c...